<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://seekingalpha.com/article/4309747-tracking-david-abrams-abrams-capital-management-portfolio-q3-2019-update"/>
    <meta property="og:site_name" content="Seeking Alpha"/>
    <meta property="article:published_time" content="2019-11-29T15:26:03+00:00"/>
    <meta property="og:title" content="Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2019 Update"/>
    <meta property="og:description" content="David Abrams' 13F portfolio value decreased this quarter from $3.68B to $3.57B. The number of positions increased from 19 to 20.Abrams Capital Management added Altaba while increasing Teva Pharmaceuti"/>
  </head>
  <body>
    <article>
      <h1>Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2019 Update</h1>
      <address><time datetime="2019-11-29T15:26:03+00:00">29 Nov 2019, 15:26</time> by <a rel="author">John Vincent</a></address>
      <p>Summary</p>
      <ul>
        <li>David Abrams' 13F portfolio value decreased this quarter from $3.68B to $3.57B. The number of positions increased from 19 to 20.</li>
        <li>Abrams Capital Management added Altaba while increasing Teva Pharmaceutical and Camping World Holdings.</li>
        <li>The top three positions are Celgene Corp., Lithia Motors, and Franklin Resources, and they add up to ~35% of the portfolio.</li>
      </ul>
      <p>This article is part of a series that provides an ongoing analysis of the changes made to David Abrams' 13F portfolio on a quarterly basis. It is based on Abrams' regulatory <a href="https://www.sec.gov/Archives/edgar/data/1358706/000117266119002340/0001172661-19-002340-index.htm">13F Form</a> filed on 11/14/2019. Please visit our <a href="http://seekingalpha.com/article/3186676-tracking-david-abrams-abrams-capital-management-portfolio-q1-2015-update">Tracking David Abrams' Abrams Capital Management</a> article for an idea on his investment philosophy and our <a href="https://seekingalpha.com/article/4284634-tracking-david-abrams-abrams-capital-management-portfolio-q2-2019-update">last update</a> for the fund's moves during Q2 2019.</p>
      <p>This quarter, Abrams' 13F portfolio value decreased ~3% from $3.68B to $3.57B. The number of holdings increased from 19 to 20. The top three stakes are at ~35% of the 13F portfolio while the top five holdings are at ~49%. The largest position is Celgene Corp. and it accounts for 18.77% of the 13F portfolio.</p>
      <p>
        <b>Stake Disposals:</b>
      </p>
      <p>
        <b>None.</b>
      </p>
      <p>
        <b>New Stakes:</b>
      </p>
      <p><b>Altaba Inc.:</b> A large (top five) ~7% Altaba stake was purchased during the quarter. Altaba made a pre-dissolution distribution of $51.50 per share in September.</p>
      <p>
        <b>Stake Decreases:</b>
      </p>
      <p>
        <b>None.</b>
      </p>
      <p>
        <b>Stake Increases:</b>
      </p>
      <p><b>Teva Pharmaceutical (<a href="https://seekingalpha.com/symbol/TEVA">TEVA</a>):</b> TEVA is currently a 4.63% of the portfolio stake. It was established in Q3 2017 at prices between $15.50 and $33.50. The stock currently trades at $10.45. This quarter saw a one-third stake increase at prices between $6 and $9.60.</p>
      <p><b>Camping World Holdings (<a href="https://seekingalpha.com/symbol/CWH">CWH</a>):</b> CWH is a 1.36% position purchased in Q3 2018 at prices between $19 and $27 and increased by two-thirds next quarter at prices between $11.25 and $22.50. Last quarter saw a ~30% stake increase at $11 and $13 per share. The stock is now near the low end of their purchase price ranges at $12.05. Abrams controls ~6% of the business.</p>
      <p>Note: Regulatory filings since the quarter ended show them owning ~6.11M shares. This is compared to 5.46M shares in the 13F report. The increase happened at ~$7.90 per share.</p>
      <p>
        <b>Kept Steady:</b>
      </p>
      <p><b>Celgene Corp. (<a href="https://seekingalpha.com/symbol/CELG">CELG</a>) and PG&amp;E Corp. (<a href="https://seekingalpha.com/symbol/PCG">PCG</a>):</b> These large stakes were established in Q1 2019. The ~19% of the portfolio CELG stake is currently their largest position. It was a merger-arbitrage stake established at ~$90. Bristol-Myers Squibb (<a href="https://seekingalpha.com/symbol/BMY">BMY</a>) agreed to acquire Celgene Corp. in a cash-and-stock transaction (one share of BMY and $50 cash along with a CVR that could pay $9 based on achieving regulatory milestones for each share held) announced in January. The deal closed last week. PCG is a ~7% position purchased at ~$7 per share and it currently goes for $7.55. PG&amp;E share price dropped sharply in mid-January as they announced plans to file for bankruptcy. Abrams along with two other hedge funds stepped in and bought 45M shares near the lows.</p>
      <p><b>Lithia Motors (<a href="https://seekingalpha.com/symbol/LAD">LAD</a>):</b> The large (top three) 8.52% LAD stake was established in Q2 2018 at prices between $95 and $105 and almost doubled next quarter at prices between $81 and $99. The stock is now at ~$164. Q4 2018 also saw a ~15% stake increase.</p>
      <p>Note: Their ownership stake in Lithia Motors is at ~10%.</p>
      <p><b>Franklin Resources (<a href="https://seekingalpha.com/symbol/BEN">BEN</a>):</b> BEN is currently the third-largest position at ~8% of the 13F portfolio. It was established in Q4 2015 at prices between $35 and $42 and increased by ~50% the following quarter at prices between $31.50 and $39. There was another ~25% stake increase in Q3 2018 at prices between $30 and $34.50. The stock currently trades at $27.88. For investors attempting to follow, BEN is a good option to consider for further research.</p>
      <p><b>AMERCO (<a href="https://seekingalpha.com/symbol/UHAL">UHAL</a>):</b> UHAL is a ~6% position purchased in Q4 2016 at prices between $314 and $374 and increased by ~160% the following quarter at prices between $367 and $391. There was a ~45% increase in Q2 2017 at prices between $341 and $393 and that was followed with a similar increase in H1 2018 at prices between $323 and $384. The stock is now at ~$365.</p>
      <p><b>Willis Towers Watson plc (<a href="https://seekingalpha.com/symbol/WLTW">WLTW</a>):</b> WLTW is a fairly large ~6% position purchased in Q1 2017 at prices between $117 and $133. The stock is now well above that range at ~$196. There was a ~6% trimming in Q4 2018.</p>
      <p><b>O'Reilly Automotive (<a href="https://seekingalpha.com/symbol/ORLY">ORLY</a>):</b> The fairly large ~6% ORLY stake was purchased in Q3 2017 at prices between $173 and $220. The stock has doubled and it currently trades at ~$446. Q4 2018 saw a minor ~3% selling and that was followed with a ~13% trimming next quarter at prices between $335 and $392. Last quarter saw another ~30% selling at prices between $353 and $409. Abrams is harvesting gains.</p>
      <p><b>Asbury Automotive (<a href="https://seekingalpha.com/symbol/ABG">ABG</a>):</b> ABG is a 5.45% position established in Q3 2017 at prices between $50 and $62 and increased by ~45% in Q3 2018 at prices between $67 and $77.50. Q4 2018 saw another 20% stake increase at prices between $59 and $72. The stock currently trades at ~$113.</p>
      <p>Note: Their ownership stake in the business is ~10%.</p>
      <p><b>Facebook (<a href="https://seekingalpha.com/symbol/FB">FB</a>):</b> FB is a 5.11% portfolio position purchased in Q4 2018 at prices between $124 and $163 and the stock currently trades well above that at ~$202. There was a marginal stake increase in Q1 2019.</p>
      <p><b>Kinder Morgan (<a href="https://seekingalpha.com/symbol/KMI">KMI</a>):</b> KMI is a 4.92% of the portfolio position purchased in Q1 2018 at prices between $14.75 and $19.75, and the stock is currently at $19.73.</p>
      <p><b>Alphabet Inc. (<a href="https://seekingalpha.com/symbol/GOOG">GOOG</a>):</b> GOOG is a 4.24% position purchased in Q2 2018 at prices between $1,005 and $1,175 and the stock is now well above that range at $1,313.</p>
      <p><b>TransMedics Group (<a href="https://seekingalpha.com/symbol/TMDX">TMDX</a>):</b> TMDX is a 2.25% of the 13F portfolio stake that came about as a result of its IPO in May. Abrams was an early investor who led funding rounds going back to 2012. The stock started trading at ~$25 and currently goes for $18.97.</p>
      <p><b>Suburban Propane Partners (<a href="https://seekingalpha.com/symbol/SPH">SPH</a>):</b> SPH is a ~2% portfolio stake established in Q2 2017 at prices between $22.75 and $27 and increased by ~75% next quarter at prices between $23.50 and $26. The position was more than doubled in Q4 2017 at prices between $23.20 and $26.70 and that was followed with a ~87% increase over the next two quarters at prices between $22 and $27. The stock is currently at $22.38.</p>
      <p><b>Sculptor Capital (<a href="https://seekingalpha.com/symbol/SCU">SCU</a>)</b> previously Och-Ziff Capital Management (OZM): SCU is a 1.21% portfolio stake established in Q2 2016 at prices between $33 and $43.50 and increased by ~11% in the following quarter at prices between $33.50 and $44.90. There was another ~11% increase in Q4 2016 at a cost-basis around $32. Q1 2017 also saw a ~17% increase at prices between $22 and $36.30. The stock is now at $19.50.</p>
      <p>Note: The prices quoted above are adjusted for the 1 for 10 reverse stock split in January.</p>
      <p><b>Pacific Drilling S.A. (<a href="https://seekingalpha.com/symbol/PACD">PACD</a>):</b> The 0.81% PACD stake got established in Q4 2018 as the company emerged from Chapter 11 bankruptcy last November. The stock is now at $2.91. Abrams Capital's ownership stake in Pacific Drilling is ~10%. They had ~$200M in Pacific Drilling debt when the company filed for bankruptcy in November 2017.</p>
      <p><b>Akebia Therapeutics (<a href="https://seekingalpha.com/symbol/AKBA">AKBA</a>):</b> AKBA was a minutely small 0.74% portfolio stake as of Q3 2018. They merged with Keryx Biopharmaceuticals (<a href="https://seekingalpha.com/symbol/KERX">KERX</a>) in a transaction that closed in December. KERX shareholders received 0.37433 common shares of AKBA for each share held. Abrams had ~9.1M shares of Keryx for which he received 3.4M shares. Abrams also increased the overall position by ~20% during Q4 2018 at prices between $5.40 and $9.15. AKBA currently trades at $5.55.</p>
      <p>Note: Their ownership stake in Akebia is at ~5%.</p>
      <p><b>Clear Channel Outdoor Holdings (<a href="https://seekingalpha.com/symbol/CCO">CCO</a>):</b> CCO is a very small 0.43% of the 13F portfolio stake. It is a very long-term position that has been in the portfolio since 2009. The stake has been kept almost steady since. In March 2012, CCO paid a special-dividend of $6.08 per share and that recouped almost the entire outlay on this investment. The stock currently trades at $2.52.</p>
      <p>The spreadsheet below highlights changes to Abrams' 13F stock holdings in Q3 2019:</p>
      <figure>
        <img src="https://static.seekingalpha.com/uploads/2019/11/29/106657-15750358296240242.jpg"/>
      </figure>
      <p><b>Disclosure:</b> I am/we are long AKBA, KMI. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p>
    </article>
  </body>
</html>